Inhibrx Biosciences, Inc. (INBX) Earnings History
Annual and quarterly earnings data from 2016 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | -1042.5% | -165724.0% | 843786.0% |
| 2023 | 33.8% | -12178.9% | -13408.9% |
| 2022 | -4926.7% | -5890.4% | -6625.3% |
| 2021 | 62.3% | -1074.6% | -1147.6% |
| 2020 | -473.8% | -526.6% | -590.5% |
Download Data
Export INBX earnings history in CSV or JSON format
Free sign-in required to download data
Inhibrx Biosciences, Inc. (INBX) Earnings Overview
As of March 1, 2026, Inhibrx Biosciences, Inc. (INBX) reported trailing twelve-month net income of -$155M, reflecting +23.8% year-over-year growth. The company earned $-10.02 per diluted share over the past four quarters, with a net profit margin of 8437.9%.
Looking at the long-term picture, INBX's historical earnings data spans multiple years. The company achieved its highest annual net income of $1.69B in fiscal 2024, representing a new all-time high.
Inhibrx Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), INBX has comparable earnings metrics. Compare INBX vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.69B | +799.2% | -$331M | $116.58 | 843786.0% | -165724.0% |
| 2023 | -$241M | -66.2% | -$219M | $-5.12 | -13408.9% | -12178.9% |
| 2022 | -$145M | -77.6% | -$129M | $-3.62 | -6625.3% | -5890.4% |
| 2021 | -$82M | -8.1% | -$77M | $-2.15 | -1147.6% | -1074.6% |
| 2020 | -$76M | -47.2% | -$67M | $-2.99 | -590.5% | -526.6% |
| 2019 | -$51M | -64.9% | -$44M | $-1.41 | -565.3% | -480.7% |
| 2018 | -$31M | -60.3% | -$30M | $-1.15 | -415.5% | -393.5% |
| 2017 | -$19M | -135.1% | -$20M | $-0.68 | -244.6% | -248.2% |
| 2016 | -$8M | - | -$12M | $-0.23 | -124.0% | -182.2% |
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INBX vs AGIO
See how INBX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is INBX growing earnings?
INBX EPS is $-10.02, with earnings growth accelerating to +23.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-155M.
What are INBX's profit margins?
Inhibrx Biosciences, Inc. net margin is +8437.9%, with operating margin at -1657.2%. Above-average margins indicate pricing power.
How consistent are INBX's earnings?
INBX earnings data spans 2016-2024. The accelerating earnings trend is +23.8% YoY. Historical data enables comparison across business cycles.